Literature DB >> 22408345

Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis.

Eduardo Garcia Vilela1, Henrique Osvaldo da Gama Torres, Fabiana Paiva Martins, Maria de Lourdes de Abreu Ferrari, Marcella Menezes Andrade, Aloísio Sales da Cunha.   

Abstract

Crohn's disease and ulcerative colitis evolve with a relapsing and remitting course. Determination of inflammatory state is crucial for the assessment of disease activity and for tailoring therapy. However, no simple diagnostic test for monitoring intestinal inflammation is available. Noninvasive markers give only indirect assessments of disease activity. Histopathological or endoscopical examinations accurately assess inflammatory activity, but they are invasive, time consuming and expensive and therefore are unsuitable for routine use. Imaging procedures are not applicable for ulcerative colitis. The usefulness of ultrasound and Doppler imaging in assessing disease activity is still a matter of discussion for Crohn's disease, and an increased interest in computed tomography enterograph (CTE) has been seen, mainly because it can delineate the extent and severity of bowel wall inflammation, besides detecting extraluminal findings. Until now, the available data concerning the accuracy of magnetic resonance enterography in detecting disease activity is less than CTE. Due to this, clinical activity indices are still commonly used for both diseases.

Entities:  

Keywords:  Crohn’s disease; Diagnostic test; Inflammatory bowel disease; Inflammatory markers; Therapy; Ulcerative colitis

Mesh:

Substances:

Year:  2012        PMID: 22408345      PMCID: PMC3297045          DOI: 10.3748/wjg.v18.i9.872

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  115 in total

1.  Intestinal permeability: functional assessment and significance.

Authors:  S Travis; I Menzies
Journal:  Clin Sci (Lond)       Date:  1992-05       Impact factor: 6.124

2.  Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses.

Authors:  R H Duerr; S R Targan; C J Landers; L R Sutherland; F Shanahan
Journal:  Gastroenterology       Date:  1991-06       Impact factor: 22.682

3.  Ultrasonographic assessment of inflammatory bowel disease.

Authors:  J Hata; K Haruma; K Suenaga; M Yoshihara; G Yamamoto; S Tanaka; T Shimamoto; K Sumii; G Kajiyama
Journal:  Am J Gastroenterol       Date:  1992-04       Impact factor: 10.864

4.  Erythrocyte sedimentation as a measure of Crohn's disease activity: opposite trends in ileitis versus colitis.

Authors:  D B Sachar; N E Luppescu; C Bodian; R D Shlien; T L Fabry; V V Gumaste
Journal:  J Clin Gastroenterol       Date:  1990-12       Impact factor: 3.062

5.  Predictability of the postoperative course of Crohn's disease.

Authors:  P Rutgeerts; K Geboes; G Vantrappen; J Beyls; R Kerremans; M Hiele
Journal:  Gastroenterology       Date:  1990-10       Impact factor: 22.682

6.  Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives.

Authors:  B Landi; T N Anh; A Cortot; J C Soule; E Rene; J P Gendre; P Bories; A See; E H Metman; C Florent
Journal:  Gastroenterology       Date:  1992-05       Impact factor: 22.682

7.  Intestinal permeability and the prediction of relapse in Crohn's disease.

Authors:  J Wyatt; H Vogelsang; W Hübl; T Waldhöer; H Lochs
Journal:  Lancet       Date:  1993-06-05       Impact factor: 79.321

8.  Evidence for continuous stimulation of interleukin-6 production in Crohn's disease.

Authors:  V Gross; T Andus; I Caesar; M Roth; J Schölmerich
Journal:  Gastroenterology       Date:  1992-02       Impact factor: 22.682

9.  Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease.

Authors:  D Foell; T Kucharzik; M Kraft; T Vogl; C Sorg; W Domschke; J Roth
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

10.  High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis.

Authors:  Y R Mahida; L Kurlac; A Gallagher; C J Hawkey
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

View more
  31 in total

1.  Patent portfolios for biotech inventions.

Authors:  Shyh-Jen Wang
Journal:  Nat Biotechnol       Date:  2013-06       Impact factor: 54.908

2.  Correlation between triggering receptor expressed on myeloid cells-1 and clinical disease activity in Chinese patients with ulcerative colitis.

Authors:  Shulan Zhang; Jing Luo; Bingbing Shen; Lijun Li; Chaojun Hu; Ping Li; Chuiwen Deng; Fengchun Zhang; Jiaming Qian; Yongzhe Li
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis.

Authors:  Emanuel Burri; Christoph Beglinger; Stefanie von Felten; Frank Serge Lehmann
Journal:  Dig Dis Sci       Date:  2014-10-26       Impact factor: 3.199

Review 4.  Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?

Authors:  Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2016-03       Impact factor: 4.409

5.  Anatomical Road Mapping Using CT and MR Enterography for Ultrasound Molecular Imaging of Small Bowel Inflammation in Swine.

Authors:  Huaijun Wang; Stephen A Felt; Ismayil Guracar; Valentina Taviani; Jianhua Zhou; Rosa Maria Silveira Sigrist; Huiping Zhang; Joy Liau; José G Vilches-Moure; Lu Tian; Yamil Saenz; Thierry Bettinger; Brian A Hargreaves; Amelie M Lutz; Jürgen K Willmann
Journal:  Eur Radiol       Date:  2017-11-23       Impact factor: 5.315

6.  The histopathological approach to inflammatory bowel disease: a practice guide.

Authors:  Cord Langner; Fernando Magro; Ann Driessen; Arzu Ensari; Gerassimos J Mantzaris; Vincenzo Villanacci; Gabriel Becheanu; Paula Borralho Nunes; Gieri Cathomas; Walter Fries; Anne Jouret-Mourin; Claudia Mescoli; Giovanni de Petris; Carlos A Rubio; Neil A Shepherd; Michael Vieth; Rami Eliakim; Karel Geboes
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

7.  Noninvasive Markers of Disease Activity in Inflammatory Bowel Disease.

Authors:  Raluca Vrabie; Sunanda Kane
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-09

8.  Inflammatory bowel disease: a proposal to facilitate the achievement of an unequivocal diagnosis.

Authors:  Gabriella Canavese; Gabrio Bassotti; Marco Astegiano; Isabella Castellano; Paola Cassoni; Anna Sapino; Vincenzo Villanacci
Journal:  World J Gastroenterol       Date:  2013-01-21       Impact factor: 5.742

9.  Relationship between neutrophil gelatinase-associated lipocalin (NGAL) levels and inflammatory bowel disease type and activity.

Authors:  Atakan Yeşil; Can Gönen; Ebubekir Senateş; Nurcan Paker; Yasemin Gökden; Koray Koçhan; Emrullah Düzgün Erdem; Feyza Gündüz
Journal:  Dig Dis Sci       Date:  2013-04-30       Impact factor: 3.199

10.  Prognostic value of assessment of stool and serum IL-1β, IL-1ra and IL-6 concentrations in children with active and inactive ulcerative colitis.

Authors:  Andrzej Wędrychowicz; Przemysław Tomasik; Andrzej Zając; Krzysztof Fyderek
Journal:  Arch Med Sci       Date:  2017-06-30       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.